Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Naratuximab emtansine |
Synonyms | |
Therapy Description |
Naratuximab emtansine (IMGN529) is an antibody-drug conjugate consisting of a humanized anti-CD37 monoclonal antibody linked to the anti-mitotic agent, maytansinoid DM1, thereby inducing cell death of B-cells expressing CD37 (PMID: 29453628, PMID: 28753442). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Naratuximab emtansine | IMGN 529|Debio 156|IMGN529 | CD37 Antibody 8 | Naratuximab emtansine (IMGN529) is an antibody-drug conjugate consisting of a humanized anti-CD37 monoclonal antibody linked to the anti-mitotic agent, maytansinoid DM1, thereby inducing cell death of B-cells expressing CD37 (PMID: 29453628, PMID: 28753442). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|